Regeneron's purchase is still subject to court ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in 1993 in Alexandria, VA., by brothers David and Tom ...

Throughout the last three months, 16 analysts have evaluated Regeneron Pharmaceuticals (NASDAQ:REGN), offering a diverse set of opinions from bullish to bearish. The following table summarizes ...

Fintel reports that on May 14, 2025, Citigroup upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Neutral to Buy. As of May 6, 2025, the average one-year price target for ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data from its oncology and hematology portfolio will be shared at the 2025 American Society of Clinical Oncology ...

In children aged 8 to 11 years, PRALUENT should be given by a caregiver. Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming ...

Looking at the universe of stocks we cover at Dividend Channel, on 5/20/25, Regeneron Pharmaceuticals, Inc. (Symbol: REGN), PROG Holdings Inc (Symbol: PRG), and Prudential Financial Inc (Symbol ...

The projected annual revenue for Regeneron Pharmaceuticals is 14,197MM ... of the author and do not necessarily reflect those of Nasdaq, Inc. Fintel is a leading provider of financial data ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has entered a key licensing agreement with Telesis Bio Inc. to integrate the ...

Fintel reports that on May 14, 2025, Citigroup upgraded their outlook for Regeneron Pharmaceuticals ... and do not necessarily reflect those of Nasdaq, Inc. Fintel is a leading provider of ...

There are 2,406 funds or institutions reporting positions in Regeneron Pharmaceuticals ... author and do not necessarily reflect those of Nasdaq, Inc. Fintel is a leading provider of financial ...

Intellia Therapeutics (NTLA) stock drops on safety concern in a Phase 3 trial for gene editing therapy nex-z developed with ...